Glaucoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Glaucoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GKOS | Glaukos Corporation | Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneNCT06848946Change from baseline in mean diurnal IOP | Phase 4 | Recruiting | Aug 2026 | ≤ 11 d | 2026-01-21 |
| SGHT | Sight Sciences, Inc. | OMNI 3.1 Surgical System in Subjects With Primary Open-Angle GlaucomaNCT06991270Primary Effectiveness Endpoint | Not applicable | Recruiting | 2026-08-31 | in 11 d | 2026-01-14 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SGHT | Sight Sciences, Inc. | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)NCT06948773≥ 20% change from baseline in mean IOP at the 3-month post-operative endpoint | Not applicable | Active, not recruiting | 2026-09-30 | in 41 d | 2026-07-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Glaucoma
most recently updated first98 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaNCT06822738Percentage of Participants With Treatment Response of Achieving ≥ 20% Reduction in Intraocular Pressure (IOP) From Baseline on the Same or Fewer Number of IOP-Lowering Medications Compared to Baseline | Phase 3 | Recruiting | Device: XEN63 Glaucoma Treatment System | Primary Open Angle Glaucoma | 130 | 2025-02-11 | Nov 2028 | ≤ 833 d | 2026-08-14 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902Change from baseline in visual field mean deviation in the study eye at Day 28/Exit. | Phase 2 | Completed | Drug: BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5% | Glaucoma | 252 | 2025-10-24 | 2026-05-18actual | — | 2026-07-22 |
| ABBV | AbbVie | $457.5B | Long-term Safety and Efficacy Extension Trial of Bimatoprost SRNCT03891446Duration of effect of Bimatoprost SR | Phase 3 | Completed | Drug: Bimatoprost SR · Other: Standard of Care | Open-Angle Glaucoma, Ocular Hypertension | 455 | 2019-03-27 | 2026-06-19actual | — | 2026-07-15 |
| SGHT | Sight Sciences, Inc. | $453M | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)NCT06948773≥ 20% change from baseline in mean IOP at the 3-month post-operative endpoint | Not applicable | Active, not recruiting | Device: Helix Surgical System | Primary Open Angle Glaucoma, Cataract | 25 | 2025-05-21 | 2026-09-30 | in 41 d | 2026-07-07 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07675824Occurrence of Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Not yet recruiting | Drug: REGN22530 | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | 271 | 2026-07-23 | 2029-07-25 | in 1,070 d | 2026-06-30 |
| SGP | SpyGlass Pharma, Inc. | $864M | Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular HypertensionNCT07641296Mean IOP change from Baseline (mmHg) | Phase 1 | Not yet recruiting | Drug: BIM-DRS Low Dose, BIM-DRS High Dose · Device: SpyGlass IOL with silicone pads (no drug) | Glaucoma, Ocular Hypertension | 24 | 2026-07-31 | 2027-02-28 | in 192 d | 2026-06-11 |
| GKOS | Glaukos Corporation | $10.9B | Travoprost Intraocular Implant + iStent InfiniteNCT06066645change from baseline in mean diurnal intraocular pressure (IOP) | Phase 4 | Recruiting | Drug: Travoprost Intraocular Implant · Device: iStent infinite · Other: Sham procedure | Glaucoma, Open-Angle | 150 | 2023-09-14 | May 2027 | ≤ 284 d | 2026-06-02 |
| ABBV | AbbVie | $457.5B | AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionNCT04499248Change from Baseline in Hour 0 Intraocular Pressure (IOP) in the Study Eye | Phase 1/2 | Active, not recruiting | Drug: AGN-193408 SR, AGN-193408 SR · Other: Lumigan, Sham Administration, Lumigan Vehicle, Sham Administration, Lumigan Vehicle | Open-angle Glaucoma, Ocular Hypertension | 100 | 2020-11-16 | Apr 2029 | ≤ 984 d | 2026-05-22 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in ChinaNCT05821855Change from Baseline in Intraocular Pressure (IOP) | Phase 4 | Active, not recruiting | Device: XEN45 Glaucoma Treatment System · Procedure: Trabeculectomy | Open-angle Glaucoma, OAG | 120 | 2024-01-09 | Jul 2030 | ≤ 1,441 d | 2026-04-28 |
| GKOS | Glaukos Corporation | $10.9B | Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantNCT07495852Intraocular pressure (IOP) | Phase 3 | Recruiting | Drug: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5% · Procedure: Sham Procedure · Other: placebo eye drops | Glaucoma | 510 | 2026-02-17 | Jun 2028 | ≤ 680 d | 2026-03-30 |
| GKOS | Glaukos Corporation | $10.9B | Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral ImplantNCT07075718Intraocular pressure (IOP) | Phase 2/3 | Recruiting | Drug: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5% · Procedure: Sham Procedure · Other: Placebo eye drops | Glaucoma | 610 | 2025-06-12 | Mar 2028 | ≤ 589 d | 2026-03-02 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle GlaucomaNCT05411198Percentage of Participants Achieving Effectiveness of XEN45 | Phase 3 | Completed | Device: XEN45 (Glaucoma Gel Stent) | Open-Angle Glaucoma | 74 | 2022-07-22 | 2026-02-04actual | — | 2026-02-27 |
| GKOS | Glaukos Corporation | $10.9B | Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery AloneNCT06848946Change from baseline in mean diurnal IOP | Phase 4 | Recruiting | Combination product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery · Procedure: Sham procedure in conjunction with cataract surgery | Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery | 132 | 2025-01-13 | Aug 2026 | ≤ 11 d | 2026-01-21 |
| SKYE | Skye Bioscience, Inc. | $13M | Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressureNCT06144918results2026-01-14Change From Baseline in Ocular Hypertension as Measured by Intraocular Pressure (IOP) | Phase 2 | Completed | Drug: SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo | Primary Open Angle Glaucoma, Ocular Hypertension | 56 | 2023-11-09 | 2024-02-22actual | — | 2026-01-14 |
| SGHT | Sight Sciences, Inc. | $453M | OMNI 3.1 Surgical System in Subjects With Primary Open-Angle GlaucomaNCT06991270Primary Effectiveness Endpoint | Not applicable | Recruiting | Device: OMNI 3.0 Surgical System | Primary Open Angle Glaucoma | 25 | Feb 2026 | 2026-08-31 | in 11 d | 2026-01-14 |
| SGHT | Sight Sciences, Inc. | $453M | Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle GlaucomaNCT02928289results2025-09-24Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg) | Not applicable | Terminatedsponsor's stated reason: Poor enrollment | Device: VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT) | Open-Angle Glaucoma | 29 | 2017-01-23 | 2019-01-17actual | — | 2025-11-14 |
| SGHT | Sight Sciences, Inc. | $453M | Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)NCT04658095results2025-10-27Mean Change in Unmedicated DIOP From Baseline at the 12-month Postoperative Examination | Not applicable | Terminatedsponsor's stated reason: Business Decision | Device: Canaloplasty and trabeculotomy with the OMNI system., iStent inject, Canaloplasty | Glaucoma, Open-Angle | 10 | 2022-01-11 | 2022-11-18actual | — | 2025-10-27 |
| SGP | SpyGlass Pharma, Inc. | $864M | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)NCT07218783Mean IOP Reduction from Baseline (mmHg) | Phase 3 | Recruiting | Drug: Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5% · Device: SpyGlass IOL, Commercial IOL | Cataract, Glaucoma, Ocular Hypertension | 400 | 2025-10-15 | 2029-03-31 | in 954 d | 2025-10-20 |
| SGP | SpyGlass Pharma, Inc. | $864M | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)NCT07218796Mean IOP Reduction from Baseline (mmHg) | Phase 3 | Recruiting | Drug: Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5% · Device: SpyGlass IOL, Commercial IOL | Cataract, Glaucoma, Ocular Hypertension | 400 | 2025-10-28 | 2029-05-31 | in 1,015 d | 2025-10-20 |
| SGP | SpyGlass Pharma, Inc. | $864M | Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle GlaucomaNCT07154797Unmedicated eyes with IOP reduction of ≥20% from Baseline to the Month 6 | Not applicable | Completed | Combination product: Bimatoprost Implant System / IOL Combination | Cataract, Ocular Hypertension, Glaucoma | 24 | 2022-04-21 | 2022-12-13actual | — | 2025-09-04 |
| SGP | SpyGlass Pharma, Inc. | $864M | Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL CombinationNCT07154810observationalUnmedicated eyes with an IOP Reduction from SGP-SPEC-001 Baseline | — | Active, not recruiting | — | Glaucoma, Cataract, Ocular Hypertension | 23 | 2023-03-16 | 2031-04-14 | in 1,698 d | 2025-09-04 |
| SGP | SpyGlass Pharma, Inc. | $864M | Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionNCT06120842Mean IOP Reduction from Baseline (mmHg) | Phase 1/2 | Active, not recruiting | Drug: Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5% · Device: Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL | Cataract, Glaucoma, Ocular Hypertension | 201 | 2023-10-13 | 2025-01-31actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionNCT03850782Retreatment or rescue administered for IOP | Phase 3 | Completed | Drug: Bimatoprost (SR) | Open-Angle Glaucoma, Ocular Hypertension | 515 | 2019-02-28 | 2025-08-08actual | — | 2025-08-19 |
| SGHT | Sight Sciences, Inc. | $453M | An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)NCT04872348results2025-05-11observationalChange in Intraocular Pressure (IOP) | — | Completed | Device: OMNI® Surgical System | Glaucoma, Open-Angle | 28 | 2021-07-01 | 2023-11-02actual | — | 2025-05-22 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)NCT05335122Efficacy Outcome: IOP changes from Baseline | Phase 2 | Completed | Drug: OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg | Open Angle Glaucoma, Ocular Hypertension | 83 | 2022-03-16 | 2024-01-24actual | — | 2025-03-21 |
| ABBV | AbbVie | $457.5B | Expanded Access to Bimatoprost (Durysta)NCT05338606expanded access | — | No longer available | Drug: Bimatoprost Sustained Release Implant | Open-angle Glaucoma | — | — | — | — | 2025-02-10 |
| SGHT | Sight Sciences, Inc. | $453M | A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle GlaucomaNCT06407973Subjects with a ≥ 20% reduction | Phase 4 | Terminatedsponsor's stated reason: Business decision by the Sponsor | Device: OMNI Surgical System · Drug: Latanoprost plus adjunctive glaucoma medication | Primary Open Angle Glaucoma | 2 | 2024-08-21 | 2025-01-20actual | — | 2025-01-29 |
| SGHT | Sight Sciences, Inc. | $453M | A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical SystemNCT05044793results2025-01-22observationalPrimary Safety Endpoint | — | Completed | Device: OMNI® Surgical System | Glaucoma, Open-Angle | 70 | 2021-09-01 | 2023-08-21actual | — | 2025-01-22 |
| GKOS | Glaukos Corporation | $10.9B | Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%NCT03519386results2023-09-14Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative | Phase 3 | Completed | Combination product: G2-TR intraocular implant containing travoprost · Drug: Sham surgery + active-comparator eye drops | Glaucoma, Open-Angle, Ocular Hypertension | 590 | 2018-07-26 | 2022-04-05actual | — | 2024-11-29 |
| GKOS | Glaukos Corporation | $10.9B | Clinical Study Comparing Two Models of a Travoprost Intraocular ImplantNCT03868124results2023-09-26Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative | Phase 3 | Completed | Combination product: G2-TR intraocular implant containing travoprost · Drug: Sham surgery + active-comparator eye drops | Glaucoma, Open-Angle, Ocular Hypertension | 560 | 2018-09-17 | 2022-06-10actual | — | 2024-11-29 |
| GKOS | Glaukos Corporation | $10.9B | Performance of the Travoprost Intraocular ImplantNCT06582732results2024-10-15Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration | Phase 2 | Completed | Drug: Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6, Travoprost Intracameral Implant exchanged at Month 24, Travoprost intracameral implant exchanged at Month 21, Travoprost intracameral implant exchanged at Month 18, Travoprost intracameral implant exchanged at Month 15 | Glaucoma, Open-Angle, Ocular Hypertension | 210 | 2021-03-10 | 2023-11-02actual | — | 2024-10-15 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular HypertensionNCT04360174results2024-10-01Ocular Treatment Emergent Adverse Events | Phase 1 | Completed | Drug: OTX-TIC | Ocular Hypertension, Open Angle Glaucoma | 19 | 2018-04-25 | 2021-05-24actual | — | 2024-10-01 |
| GKOS | Glaukos Corporation | $10.9B | Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. CompetitorNCT05127551Change in Mean Diurnal Intraocular Pressure | Not applicable | Active, not recruiting | Device: iStent Infinite, Competitor Device | Glaucoma, Glaucoma, Open-Angle | 179 | 2021-11-27 | 2024-02-29actual | — | 2024-08-15 |
| SGHT | Sight Sciences, Inc. | $453M | Study of OMNI System in OAG (GEMINI)NCT03861169results2024-08-14Change in Mean Unmedicated Diurnal IOP | Not applicable | Completed | Device: Transluminal viscoelastic delivery and trabeculotomy | Open Angle Glaucoma | 209 | 2019-03-11 | 2021-05-04actual | — | 2024-08-14 |
| AMRX | Amneal Pharmaceuticals, LLC | $5.8B | A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesNCT06267274Primary Endpoint | Phase 1 | Recruiting | Drug: Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01% | Open-angle Glaucoma, Ocular Hypertension | 240 | 2024-04-01 | 2025-03-01 | — | 2024-08-06 |
| GKOS | Glaukos Corporation | $10.9B | Travoprost Intraocular Implant in Conjunction With Cataract SurgeryNCT06061718Change from baseline in mean diurnal IOP | Phase 3 | Unknown status | Drug: iDose TR | Open Angle Glaucoma, Ocular Hypertension | 60 | 2023-09-11 | 2024-03-18actual | — | 2024-06-03 |
| ABBV | AbbVie | $457.5B | Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular HypertensionNCT02507687results2024-05-10Change From Baseline in Intraocular Pressure at Week 4 | Phase 3 | Completed | Drug: Bimatoprost SR, Sham Bimatoprost SR · Procedure: Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty | Glaucoma, Open-Angle, Ocular Hypertension | 240 | 2015-08-27 | 2021-11-24actual | — | 2024-05-10 |
| GKOS | Glaukos Corporation | $10.9B | iStent Inject New Enrollment Post-Approval StudyNCT04624698iStent inject placement and stability | Not applicable | Unknown status | Device: iStent Inject Implantation | Glaucoma, Open-Angle, Glaucoma | 358 | 2020-09-22 | May 2026 | — | 2024-02-23 |
| GKOS | Glaukos Corporation | $10.9B | Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular HypertensionNCT06152861change from baseline in mean diurnal IOP in the study eye | Phase 2 | Unknown status | Drug: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004% | Open Angle Glaucoma, Ocular Hypertension | 250 | 2023-11-15 | Aug 2024 | — | 2023-12-06 |
| GKOS | Glaukos Corporation | $10.9B | Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle GlaucomaNCT06057051Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline | Not applicable | Recruiting | Device: iStent Infinite | Glaucoma | 245 | 2023-09-01 | Aug 2025 | — | 2023-09-28 |
| GKOS | Glaukos Corporation | $10.9B | Study of Exchange of Travoprost Intraocular ImplantNCT04615403results2023-09-26Ocular Safety | Phase 2 | Completed | Drug: Travoprost | Open Angle Glaucoma | 33 | 2020-11-19 | 2022-02-28actual | — | 2023-09-26 |
| ABBV | AbbVie | $457.5B | A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular HypertensionNCT04285580results2023-06-08Change From Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR Treated Eyes | Phase 3 | Completed | Drug: Bimatoprost SR, LUMIGAN | Open-Angle Glaucoma, Ocular Hypertension | 37 | 2020-06-11 | 2022-05-14actual | — | 2023-06-08 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT01722604results2021-06-09Intraocular Pressure (IOP) at Week 12 | Phase 3 | Completed | Drug: brinzolamide 1% ophthalmic suspension, Azopt 1% | Glaucoma, Open Angle or Ocular Hypertension | 258 | Jan 2012 | Sep 2012actual | — | 2023-05-09 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT03896633results2021-06-09Intraocular Pressure (IOP) | Phase 1/2 | Completed | Drug: brinzolamide 1% ophthalmic suspension, Azopt 1% | Glaucoma, Open Angle or Ocular Hypertension | 637 | 2018-02-28 | 2018-11-17actual | — | 2023-05-09 |
| GKOS | Glaukos Corporation | $10.9B | Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser TrabeculoplastyNCT02327312IOP reduction | Not applicable | Terminated | Device: Stents, Laser Trabeculoplasty · Procedure: Laser | Primary Open-Angle Glaucoma | 91 | 2014-12-16 | 2019-05-31actual | — | 2022-12-22 |
| SGHT | Sight Sciences, Inc. | $453M | A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle GlaucomaNCT04616573results2022-12-01Change in Unmedicated Diurnal Intraocular Pressure (DIOP) | Not applicable | Terminatedsponsor's stated reason: Sponsor decision | Device: OMNI® Surgical System, iStent inject | Glaucoma, Open-Angle | 1 | 2020-11-13 | 2021-01-20actual | — | 2022-12-01 |
| GKOS | Glaukos Corporation | $10.9B | Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent SupraNCT0325578520% IOP reduction from baseline | Not applicable | Completed | Device: Cataract surgery plus one iStent and one iStent Supra implanted | Glaucoma, Open-Angle | 15 | 2018-05-01 | 2019-12-03actual | — | 2022-09-09 |
| GKOS | Glaukos Corporation | $10.9B | A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent SupraNCT0325579820% IOP reduction | Not applicable | Terminatedsponsor's stated reason: Business decision | Device: G2 and G3 | Glaucoma, Open-Angle | 7 | 2017-08-01 | 2019-06-06actual | — | 2022-09-09 |
| GKOS | Glaukos Corporation | $10.9B | iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive MedicationsNCT03478293IOP reduction at 12 and 24 months on same number or fewer medications | Not applicable | Terminatedsponsor's stated reason: Business Decision | Device: iStent inject surgery | Primary Open Angle Glaucoma (POAG) | 6 | 2018-02-27 | 2020-12-30actual | — | 2022-09-09 |
| GKOS | Glaukos Corporation | $10.9B | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or TravoprostNCT01444040Change from screening in mean diurnal IOP (mm Hg) at the Month 12 visit. | Phase 4 | Completed | Device: iStent inject · Drug: Travoprost | Open-angle Glaucoma | 196 | Sep 2011 | 2019-03-28actual | — | 2022-09-08 |
| GKOS | Glaukos Corporation | $10.9B | Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive MedicationNCT02868190Mean intraocular pressure reduction of 20% or more vs baseline | Phase 4 | Completed | Device: Two trabecular micro-bypass stents (iStent inject) | Open Angle Glaucoma | 57 | Mar 2013 | 2019-11-08actual | — | 2022-09-08 |
| GKOS | Glaukos Corporation | $10.9B | Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStentsNCT01252888mean diurnal IOP reduction of greater than or equal to 20% at Month 12 vs baseline | Phase 4 | Completed | Device: iStents | Subjects With Primary Open-angle Glaucoma (POAG) | 39 | Dec 2010 | Jul 2016actual | — | 2022-09-07 |
| GKOS | Glaukos Corporation | $10.9B | Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass StentsNCT01456390Subjects observed at Month 12 who experience a mean medicated diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOP | Not applicable | Completed | Device: iStent and iStent supra | Open-Angle Glaucoma | 79 | Sep 2011 | 2019-03-26actual | — | 2022-09-07 |
| GKOS | Glaukos Corporation | $10.9B | Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive AgentsNCT02873806Mean intraocular pressure reduction of 20% or more versus baseline with reduction of 1 medication | Phase 4 | Completed | Procedure: Implantation of two iStent inject micro-bypass stents · Drug: Topical travoprost, Tobramycin, Dexamethasone · Device: Two iStent inject micro-bypass stents | Open-angle Glaucoma | 53 | Mar 2013 | 2019-11-08actual | — | 2022-09-07 |
| GKOS | Glaukos Corporation | $10.9B | Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsNCT01252849Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs. baseline | Not applicable | Completed | Device: iStent, iStent, iStent | Primary Open Angle Glaucoma (POAG) | 119 | Dec 2010 | 2019-10-08actual | — | 2022-08-31 |
| GKOS | Glaukos Corporation | $10.9B | Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser TrabeculoplastyNCT01444105Change from baseline in mean diurnal IOP (mm Hg) at the Month 12 visit. | Not applicable | Completed | Device: iStent · Other: SLT | Open-angle Glaucoma | 80 | Sep 2011 | 2019-04-09actual | — | 2022-08-31 |
| GKOS | Glaukos Corporation | $10.9B | Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract SurgeryNCT01455467Mean diurnal IOP reduction of ≥ 20% vs. baseline mean diurnal IOP | Not applicable | Completed | Device: One iStent, Two iStent | Open-angle Glaucoma | 79 | Sep 2011 | 2019-10-18actual | — | 2022-08-31 |
| GKOS | Glaukos Corporation | $10.9B | One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma SubjectsNCT01517477Mean diurnal intraocular pressure (IOP) reduction of greater than or equal to 20% at month 12 vs. baseline | Not applicable | Completed | Device: iStent, iStent, iStent | Primary Open Angle Glaucoma (POAG) | 119 | Jan 2012 | 2019-10-18actual | — | 2022-08-31 |
| AMRX | Amneal Pharmaceuticals, LLC | $5.8B | Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.NCT05401357Mean difference in the intraocular pressure (IOP) of both eyes between the two treatment groups. | Phase 3 | Recruiting | Drug: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) | Glaucoma, Open-Angle, Ocular Hypertension | 168 | 2022-06-29 | Dec 2022 | — | 2022-08-10 |
| SGHT | Sight Sciences, Inc. | $453M | A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle GlaucomaNCT04465630results2022-06-07Change in Intraocular Pressure (IOP) | Not applicable | Terminatedsponsor's stated reason: Sponsor Decision | Device: OMNI® Surgical System | Glaucoma, Open-Angle | 78 | 2020-06-19 | 2021-03-02actual | — | 2022-06-28 |
| GKOS | Glaukos Corporation | $10.9B | Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract SurgeryNCT01461278≥ 20% Reduction in Intraocular Pressure (IOP) | Not applicable | Completed | Device: iStent supra · Procedure: Cataract surgery | Primary Open-angle Glaucoma | 505 | 2011-12-22 | 2019-03-13actual | — | 2022-05-19 |
| GKOS | Glaukos Corporation | $10.9B | Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract SurgeryNCT01461291≥ 20% Reduction in Intraocular Pressure (IOP) | Not applicable | Completed | Device: iStent inject · Procedure: Cataract surgery | Primary Open-angle Glaucoma | 505 | 2012-01-16 | 2017-08-04actual | — | 2022-05-19 |
| CANF | Can-Fite BioPharma | — | Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular PressureNCT01033422results2019-05-23Intraocular Pressure in mmHg | Phase 2 | Completed | Drug: CF101, Placebo for | Ocular Hypertension, Glaucoma | 89 | Oct 2010 | Dec 2016actual | — | 2022-05-12 |
| GKOS | Glaukos Corporation | $10.9B | Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract SurgeryNCT01841450Rate of sight-threatening adverse events | Not applicable | Unknown status | Device: iStent · Procedure: Cataract surgery | Primary Open Angle Glaucoma | 360 | Jul 2013 | Aug 2021actual | — | 2021-10-20 |
| GKOS | Glaukos Corporation | $10.9B | iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval StudyNCT04624685observationaliStent inject Placement and Stability | — | Unknown status | — | Glaucoma, Open-Angle | 475 | 2020-01-15 | 2021-01-20actual | — | 2021-10-20 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHTNCT02914509results2021-10-11Mean IOP | Phase 3 | Completed | Drug: Travoprost · Other: Placebo Vehicle | Open Angle Glaucoma, Ocular Hypertension | 565 | 2016-11-07 | 2019-03-30actual | — | 2021-10-11 |
| PFE | Pfizer | $155.3B | A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329NCT00934089results2021-05-03Change From Baseline in Mean Intra Ocular Pressure (IOP) in Study Eye at Day 14: 8 Ante Meridiem (AM) (0 Hour) | Phase 2 | Completed | Drug: PF-04217329, latanoprost vehicle, PF-04217329, latanoprost | Glaucoma, Open-Angle, Ocular Hypertension | 31 | Jan 2010 | Jun 2010actual | — | 2021-05-03 |
| PFE | Pfizer | $155.3B | Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.NCT00572455results2021-04-30Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I | Phase 2 | Completed | Drug: PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, PF-04217329 - Low Dose, Latanoprost Vehicle, PF-04217329 - Middle Dose, Latanoprost Vehicle, PF-04217329 - High Dose, Latanoprost 0.005%, PF-04217329 - Low Dose, Latanoprost 0.005%, PF-04217329 - Middle Dose, Latanoprost 0.005%, PF-04217329 - High Dose, Latanoprost 0.005%, PF-04217329 - Vehicle | Primary Open-Angle Glaucoma, Ocular Hypertension | 318 | 2007-12-11 | 2009-06-26actual | — | 2021-04-30 |
| GKOS | Glaukos Corporation | $10.9B | Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaNCT03639870Primary effectiveness endpoint | Not applicable | Unknown status | Device: Model iS3 three-stent trabecular micro-bypass system | Glaucoma | 65 | 2018-07-10 | Sep 2021 | — | 2021-04-23 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for GlaucomaNCT00441883results2020-08-27Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 | Phase 2 | Completed | Drug: PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle | Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma | 176 | Mar 2007 | Feb 2008actual | — | 2020-09-14 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.NCT00595101results2020-08-27Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 | Phase 2 | Completed | Drug: PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle, Latanoprost Vehicle | Primary Open Angle Glaucoma, Ocular Hypertension | 117 | Dec 2007 | Jun 2008actual | — | 2020-09-14 |
| ANNX | Annexon, Inc. | $819M | Single-dose Study of ANX007 in Participants With Primary Open-angle GlaucomaNCT03488550Safety and tolerability as measured by the occurrence of adverse events | Phase 1 | Completed | Biological: ANX007 | Open-angle Glaucoma | 9 | 2018-03-23 | 2018-08-03actual | — | 2020-08-20 |
| ANNX | Annexon, Inc. | $819M | Study of ANX007 in Participants With Primary Open-angle GlaucomaNCT04188015To evaluate the safety and tolerability of ANX007 in participants with primary open-angle glaucoma as measured by occurrence of treatment-emergent adverse events. | Phase 1 | Completed | Biological: 2.5mg ANX007, 5.0mg ANX007 · Other: Sham Procedure | Open Angle Glaucoma | 17 | 2018-07-25 | 2019-06-03actual | — | 2020-08-20 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749930results2018-11-21Mean IOP | Phase 3 | Completed | Drug: BOL-303259-X, Timolol, BOL-303259-X | Open-Angle Glaucoma, Ocular Hypertension | 420 | Jan 2013 | May 2015actual | — | 2018-11-21 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749904results2018-11-07Mean IOP | Phase 3 | Completed | Drug: BOL-303259-X, Timolol, BOL-303259-X | Open-Angle Glaucoma, Ocular Hypertension | 420 | 2013-01-31 | 2015-06-02actual | — | 2018-11-07 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01707381results2018-09-0424 Hour IOP | Phase 2 | Completed | Drug: BOL-303259-X, Timolol maleate | Ocular Hypertension, Open Angle Glaucoma | 25 | Nov 2012 | Dec 2013actual | — | 2018-09-04 |
| BLCO | Bausch & Lomb Incorporated | $6.1B | Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHTNCT01895972results2018-06-06Change From Baseline in Intraocular Pressure | Phase 3 | Completed | Drug: Latanoprostene bunod | Glaucoma, Ocular Hypertension | 130 | 2013-07-05 | 2015-04-02actual | — | 2018-07-26 |
| GKOS | Glaukos Corporation | $10.9B | A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients.NCT00326066Efficacy | Not applicable | Completed | Device: Glaucoma Surgery · Procedure: cataract surgery only | Open-Angle Glaucoma | 47 | Feb 2005 | May 2013actual | — | 2018-03-09 |
| GKOS | Glaukos Corporation | $10.9B | A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle GlaucomaNCT00323284results2012-10-04Intraocular Pressure (Measured in mm Hg) Less or Equal to 21 mm Hg on no Topical Hypotensive Meds | Phase 3 | Completed | Device: iStent plus Cataract Surgery · Procedure: Cataract surgery only | Open-Angle Glaucoma | 240 | Jun 2005 | Jul 2009actual | — | 2018-01-12 |
| GKOS | Glaukos Corporation | $10.9B | Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStentsNCT01252862Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs baseline | Phase 4 | Completed | Device: iStent | Subjects With Primary Open-angle Glaucoma (POAG) | 40 | Dec 2010 | Jul 2016actual | — | 2017-12-18 |
| GKOS | Glaukos Corporation | $10.9B | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or TravoprostNCT01443988Change from screening in mean diurnal IOP (mm Hg) at the Month 12 visit. | Phase 4 | Completed | Device: iStent · Drug: Travoprost | Open-angle Glaucoma | 101 | Sep 2011 | Jan 2017actual | — | 2017-12-18 |
| GKOS | Glaukos Corporation | $10.9B | Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket RegistryNCT01841437observationalRate of sight-threatening adverse events | — | Completed | Device: iStent | Primary Open-angle Glaucoma | 191 | Sep 2013 | 2016-02-16actual | — | 2017-12-18 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular HypertensionNCT02312544Difference in the mean change from baseline average diurnal IOP between treatment groups at the Day 60 Visit | Phase 2 | Completed | Drug: OTX-TP, Timolol | Glaucoma, Ocular Hypertension | 72 | Nov 2014 | Sep 2015actual | — | 2016-12-14 |
| OCUL | Ocular Therapeutix, Inc. | $2.4B | Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle GlaucomaNCT01845038Mean IOP change from baseline | Phase 1 | Completed | Drug: OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-TPb ~3µg/day over 3 months with natural tears drops, Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug | Glaucoma | 41 | Apr 2013 | Mar 2014actual | — | 2016-12-12 |
| GKOS | Glaukos Corporation | $10.9B | Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket CohortNCT01836042results2016-04-15observationalRate of Sight-threatening Adverse Events | — | Completed | — | Primary Open Angle Glaucoma | 108 | Jul 2013 | Apr 2014actual | — | 2016-04-15 |
| LXRX | Lexicon Pharmaceuticals | $1.1B | Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionNCT01528111Number of subjects experiencing an adverse event | Phase 1/2 | Completed | Drug: LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle | Primary Open-angle Glaucoma, Ocular Hypertension | 63 | Mar 2012 | Jun 2012actual | — | 2015-09-14 |
| GKOS | Glaukos Corporation | $10.9B | A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.NCT00326014Efficacy | Phase 4 | Completed | Device: iStent | Open-Angle Glaucoma | 58 | Apr 2003 | Mar 2008actual | — | 2015-06-08 |
| GKOS | Glaukos Corporation | $10.9B | A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle GlaucomaNCT00911924IOP 18 mm Hg or less without medications | Phase 4 | Completed | Device: iStent | Glaucoma, Eye Diseases, Glaucoma, Open-Angle | 112 | May 2009 | Sep 2013actual | — | 2015-05-20 |
| GKOS | Glaukos Corporation | $10.9B | Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)NCT00913029Mean intraocular pressure (IOP) | Phase 4 | Completed | Device: iStent · Drug: latanoprost/timolol | Eye Diseases, Glaucoma, Open-Angle, Glaucoma | 192 | May 2009 | Sep 2012actual | — | 2015-05-20 |
| GKOS | Glaukos Corporation | $10.9B | GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle GlaucomaNCT01052558Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit. | Phase 3 | Completed | Device: iStent Inject (GTS400) · Procedure: Cataract Surgery | Glaucoma | 164 | Jan 2010 | Dec 2013actual | — | 2015-05-19 |
| GKOS | Glaukos Corporation | $10.9B | Safety and Efficacy of the GTS400 Stent in Conjunction With CataractNCT00721968results2014-03-06Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications | Phase 3 | Completed | Device: Glaucoma Stent Surgery (GTS400 Stent) · Procedure: cataract surgery alone | Open-angle Glaucoma | 62 | Mar 2007 | Feb 2012actual | — | 2014-03-06 |
| GKOS | Glaukos Corporation | $10.9B | A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2NCT00326079Efficacy | Phase 4 | Unknown status | Device: Stent | Open-Angle Glaucoma | 61 | Aug 2004 | May 2013 | — | 2013-03-29 |
| OPK | OPKO Health, Inc. | $1.0B | A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)NCT00834223Primary efficacy measure: The percentage change in IOP from baseline to 6 months and 12 months post-implantation. | Not applicable | Completed | Device: Aquashunt | Glaucoma | 15 | Jan 2009 | Sep 2009actual | — | 2011-04-01 |
| PFE | Pfizer | $155.3B | A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular HypertensionNCT00751127to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment. | Phase 3 | Completed | Drug: PhXA41, timolol | Glaucoma, Open Angle Glaucoma, Ocular Hypertension | 268 | Jan 1993 | Feb 1994actual | — | 2011-03-25 |
| PFE | Pfizer | $155.3B | A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular HypertensionNCT00150267Incidence of increase of iris pigmentation | Phase 3 | Completed | Drug: Xalacom | Glaucoma, Open-Angle, Ocular Hypertension | 976 | Feb 2002 | — | — | 2008-11-05 |
| GKOS | Glaukos Corporation | $10.9B | A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma SubjectsNCT00326040Efficacy | Phase 4 | Completed | Device: Glaucoma Surgery | Open-Angle Glaucoma | 45 | Apr 2003 | — | — | 2008-07-25 |
| PFE | Pfizer | $155.3B | Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.NCT00140062Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months. | Phase 4 | Completed | Drug: latanoprost 0.005% (Xalatan) | Ocular Hypertension, Glaucoma, Open-Angle | 329 | Feb 2002 | — | — | 2008-04-07 |
| NVS | Novartis | — | Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular HypertensionNCT00515424Rates of adverse events and serious adverse events, as well as changes in ophthalmic evaluations, laboratory values, ECGs and vital signs over period of 7 days treatment. | Phase 1 | Completed | Drug: RKI983 | Glaucoma, Ocular Hypertension | 90 | Jul 2007 | — | — | 2007-12-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Glaucoma is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Glaucoma
- Glaucoma, Open-Angle
- Open-Angle Glaucoma
- Open Angle Glaucoma
- Primary Open Angle Glaucoma
- Primary Open Angle Glaucoma (POAG)
- Primary Open-angle Glaucoma
- Subjects With Primary Open-angle Glaucoma (POAG)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Glaucoma” (a text search, wider than this page)